Molecular Diagnosis of Lung Cancer
|
|
- Jacob Short
- 5 years ago
- Views:
Transcription
1 Molecular Diagnosis of Lung Cancer Lucian R. Chirieac, M.D. Assistant Professor of Pathology Harvard Medical School Staff Pathologist, Department of Pathology Brigham and Women's Hospital 75 Francis Street Boston, MA Phone: Fax:
2 INTRODUCTION Approximately cases of lung cancer were diagnosed in the United States in 2009, accounting for about 15% of all new cancers.[1] Unfortunately, the 5-year overall survival rate did not change substantially in the past 30 years and is 15% despite current therapeutic approaches [2]. Lung cancer is one of the most challenging cancers to treat and the standard therapy includes surgical resection, platinum-based chemotherapy, and radiation therapy alone or in combination. New research involves new targeted therapies and milder treatment regimens that improve survival. Although improvements seen in the trials are modest, the hope is that an increased number of biomarkers will be available in the near future to help clinicians predict which patients are most likely to benefit from such therapies. This presentation focuses on the molecular biomarkers that help identify patients that will benefit from targeted therapies, describes the basic molecular biology principles and selected molecular diagnostic techniques and the pathological features correlated with molecular abnormalities in lung cancer. Lastly, new molecular abnormalities described in lung cancer that are predictive to novel promising targeted agents in various phases of clinical trials are discussed. This is particularly important since investigation and analysis of lung cancer for particular abnormalities expands the expertise of the pulmonary oncologic pathologist, who in addition to conventional pathologic analysis of surgical lung specimens will determine the molecular abnormalities of lung cancer that may be able to predict for sensitivity and resistance to various chemotherapeutic agents and targeted therapies [3] 2
3 MOLECULAR ALTERATIONS IN LUNG CANCER In the past years, given the development of new targeted therapies, tremendous efforts are directed towards identifying potentially drugable molecular alterations, especially against known activating mutations. Although numerous mutations have been described in lung adenocarcinoma[4] the mutation status remains unknown in more than 50% of cases.[5] Despite these efforts, so far we can identify at the present moment therapeutic targets in only 20% of lung cancers. Genotype Phenotype Correlations in Lung Cancer The current classification of lung adenocarcinoma by the World Health Organization recognizes several distinct morphologic subtypes of adenocarcinoma: papillary, acinar, solid and bronchioloalveolar [6]. However, the majority of lung adenocarcinomas exhibit combinations of morphologic patterns and are categorized as mixed subtype [6-8]. While the biologic basis for the histologic subtypes remains an area of active investigation [8], there is evidence that some subtypes may be associated with specific molecular alterations [8-13] or a better outcome [14-16]. Lung cancers with EGFR abnormalities EGFR Recognized mechanisms of EGFR gain of function in NSCLC include somatic activating mutations in the exons encoding the tyrosine kinase domain and EGFR gene amplification [17, 18]. The EGFR mutation status is determined by gene sequencing, gene copy number determined 3
4 by fluorescence in situ hybridization (FISH) or chromogenic in-situ hybridization (CISH), and protein expression determined by immunohistochemistry (IHC). Several mutations have been recently described in the TK domain of EGFR [17, 19]. Epidermal growth factor receptor (EGFR) is expressed in 50% of NSCLCs, and its expression is correlated with poor prognosis [20]. These two factors make EGFR and its family members prime candidates for the development of targeted therapeutics [21]. EGFR gene amplification predicts response to TKI therapy in at least a subset of NSCLC patients. EGFR gene amplification is detected in some EGFR-mutation positive patients as well, and it is reported to be associated with disease progression.[22] A subset of lung adenocarcinomas has activation of growth factor receptor (EGFR) by mutations and/or amplification but the interaction between them is complex and unclear. Sholl et al studied a unique cohort known to have a high prevalence of EGFR mutations using novel techniques, including EGFR-mutation-specific immunohistochemistry, the authors showed that EGFRamplified lung adenocarcinomas have distinct genetic alterations, unique clinicopathologic features and worsened prognosis.[22, 23] Furthermore, EGFR amplification and EGFR mutations are heterogenously distributed within any given tumor. These are novel and important findings with implications for the efficacy of treatment with tyrosine kinase inhibitors in patients with EGFR-mutant lung adenocarcinoma.[22] Recent reports suggest that chromogenic in-situ hybridization (CISH) can serve as a reliable alternative to FISH in determining EGFR copy number status in NSCLC. [24]. While FISH is an established modality for assessing gene amplification in the case of EGFR in NSCLC, it is an expensive and time-consuming assay that requires a special protocol, materials and a fluorescent microscope. In contrast, chromogenic in situ hybridization (CISH) utilizes a peroxidase reaction 4
5 to detect the locus of interest, can be carried out in an immunohistochemistry laboratory and is interpreted by standard light microscopy [24]. The EGFR status determined by gene sequencing, gene copy number determined by fluorescence in situ hybridization (FISH), and protein expression determined by immunohistochemistry may each contribute important information regarding which patients are likely to benefit from EGFR TKI therapy [25]. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR), have prognostic significance since patients with EGFR-mutant NSCLC have prolonged survival compared with those with wild-type disease, regardless of the treatment received [3, 26]. Although EGFR mutations are predictive of response to EGFR tyrosine kinase inhibitor (TKI) therapy, they do not appear to be predictive of a differential effect on survival. Alternatively, the other EGFR markers, protein expression determined by immunohistochemistry or gene amplification determined by FISH or CISH, are better predictors of a survival benefit from EGFR TKI [24, 27]. EGFR pathway is the best current example in lung cancer that consists of the EGFR mutations and amplification that identify patients with nonsmall-cell lung cancer who respond preferentially to EGFR tyrosine kinase inhibitors. Genotype-Phenotype Correlations In patients with lung adenocarcinoma treated with erlotinib and gefitinib, favorable responses were associated with adenocarcinoma with bronchioloalveolar (BAC) patterns.[12] This finding led to trials of gefitinib and erlotinib in patients with BAC that showed that 17%-22% of patients had a response to gefitinib.[28, 29] The relationship of EGFR mutation status with adenocarcinoma subtype is a matter of intense debate.[30, 31] Genetic abnormalities can be seen 5
6 in different histologies although with various frequency. One characteristic correlation is that mucinous adenocarcinoma (former mucinous BAC) is exclusively TTF1 negative, EGFR mutation negative but may have Ras mutation, and expresses CDX2 because of their derivation from bronchiolar mucinous goblet cells.[9] Lung cancers with ALK abnormalities Anaplastic large cell lymphoma kinase gene (ALK) was originally identified through cloning of the t(2;5)(p23;35) translocation found in a subset of anaplastic large cell lymphomas (ALCLs), a tumor of T-cell lineage [32, 33]. ALK encodes a tyrosine kinase receptor that is normally expressed only in select neuronal cell types. In ALK-rearranged anaplastic large cell lymphomas (ALCLs), the intracytoplasmic portion of ALK is fused to the N-terminal portion of nucleophosmin (NPM) resulting in a chimeric protein with constitutive kinase activity. Several other balanced translocations involving ALK have been discovered in ALCLs; however the various resulting chimeric proteins all retain the ALK kinase domain [34]. The importance of the kinase activity is exemplified by ALK-rearranged ALCL cell lines which are dependent upon ALK enzymatic activity for growth and survival. Recently, ALK rearrangements were identified in rare non-small cell lung cancer (NSCLC) cell lines and in isolated primary adenocarcinomas from Japanese and Chinese populations [35, 36]. The majority of the ALK rearrangements within NSCLCs result from an interstitial deletion and inversion in chromosome 2p and result in the EML4-ALK fusion gene product [35, 36]. EML4 encodes Echinoderm microtubule associated protein-like 4- a protein that may function in microtubule assembly. Transgenic mice expressing EML4-ALK within the lung epithelium develop numerous tumors, thereby confirming the oncogenic nature of the 6
7 mutant protein [37]. Murine tumors and human cell lines expressing EML-ALK are sensitive to inhibitors of ALK kinase activity [37, 38]. Together these data indicate that, like EGFR, ALK is an important molecular target in lung carcinoma. Thus, it will be critical to efficiently and accurately identify those lung adenocarcinomas that harbor ALK rearrangements in routine practice in order to guide the appropriate clinical therapy. None of ALK-rearranged adenocarcinomas showed coexistent mutations in EGFR. Recently published studies show that ALK-rearranged adenocarcinomas are more likely to present in younger patients with a history of never-smoking, and at higher stage relative to those without ALK rearrangements (ALK germline).[39] The majority of ALK-rearranged adenocarcinomas had a distinct histology represented by solid tumor growth and frequent signetring cells with abundant intracellular mucin.[39] Furthermore, the routine screening for ALK rearrangements in lung adenocarcinomas is challenging and recently developed antibodies show promise for applicability in the clinical laboratory.[40] A novel, recently described monoclonal antibody with increased sensitivity for ALK, uses an IHC assay that correctly identifies ALKrearranged lung adenocarcinoma with high reproducibility. This assay will facilitate the identification of ALK-rearranged lung adenocarcinomas and thereby better direct patients to appropriate treatment regimens in clinical trials.[40] Other Molecular Abnormalities That Show Promise for Targeted Therapies in Lung Cancer HER-2 Unlike the other members of the HER family, HER-2 is not strictly a receptor tyrosine kinase because no high-affinity endogenous ligand has been identified. HER-2 acts as a signaling 7
8 network coordinator and amplifier when it heterodimerizes with other HER family members. HER-2 mutations occur in 2% of NSCLCs [41, 42]. They are in-frame insertions in exon 20 and have targeted the corresponding TK domain region, as in EGFR-insertion mutations. These mutations occur in the same subpopulation as those with EGFR mutations (adenocarcinoma, never-smoker, East Asian, and women) [31]. HER-2 is frequently overexpressed in NSCLC and appears to be associated with drug resistance, increased metastatic potential, increased production of vascular endothelial growth factor (VEGF), and poor prognosis.[43]. Trastuzumab (Herceptin) is a chimerized monoclonal antibody against HER-2. Combinations of trastuzumab and chemotherapy are well tolerated, with response rates of 21% to 40%.[44] One trial showed that patients whose tumors highly overexpressed HER-2 (3+) by immunohistochemistry or evidence of amplification by FISH showed a good response. It appears that highly overexpressing HER-2 cases of NSCLC (3+ by immunohistochemistry), although relatively infrequent (3% to 9%), may show benefit with treatment with trastuzumab. c-kit The RTK c-kit is highly expressed in SCLC (although it is not mutated), and this has led to clinical trials with the specific c-kit inhibitor (STI-571, Glivec, Novartis), alone and in combination therapy. VEGF Antibodies against the angiogenic factor VEGF and small molecules against VEGF receptors, such as SU5416, which is an inhibitor of Flk-1 receptor, are being tested in NSCLC and other tumor types. More recently, modification of gene expression using sirnas has the promise of being the most powerful tool yet. 8
9 CONCLUSIONS Surgical excision remains the only therapeutic modality that can cure selected lung cancer patients. Pathologists play an important role in the surgical management of patients with lung cancer, from preoperative diagnosis and staging, to intraoperative evaluation of the extent of distant disease and margin status, to postoperative assessment of tumor genetic alterations. Furthermore, classification algorithms based on the presence of genetic alterations found in lung cancer can be used to identify drugs or therapeutic agents targeting these alterations. The clinical application of molecular diagnostic techniques has allowed a more precise and rapid assessment of lung cancer. In this era of genomics and proteomics, there is an expectation of significant advances in early diagnosis of lung cancer, the elucidation of new relevant categories of disease, and the development of more targeted therapy. Specific disease profiles may be generated for individual patients to assist in the selection of therapy, and individualized therapy may be present in the future. Understanding the molecular events underlying pathogenic processes will hopefully translate into developing curative systemic therapy and improved patient survival. 9
10 REFERENCES 1. Jemal, A., et al., Cancer statistics, CA Cancer J Clin, (4): p Jemal, A., et al., Cancer statistics, CA Cancer J Clin, (2): p Eberhard, D.A., et al., Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol, (25): p Ding, L., et al., Somatic mutations affect key pathways in lung adenocarcinoma. Nature, (7216): p Herbst, R.S., J.V. Heymach, and S.M. Lippman, Lung cancer. N Engl J Med, (13): p Travis, W., Pathology and genetics of tumours of the lung, pleura, thymus and heart. World Health Organization, International Agency for Research on Cancer., International Association for the Study of Lung Cancer., International Academy of Pathology. 2004, Lyon: IARC Press. 7. Barletta, J.A., et al., Clinical Significance of TTF-1 Protein Expression and TTF-1 Gene Amplification in Lung Adenocarcinoma. J Cell Mol Med, Motoi, N., et al., Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol, (6): p Finberg, K.E., et al., Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn, (3): p Haneda, H., et al., Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung. Lung Cancer, (1): p Hsieh, R.K., et al., Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest, (1): p Miller, V.A., et al., Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol, (6): p Matsumoto, S., et al., Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma. Int J Cancer, (10): p Jackman, D.M., L.R. Chirieac, and P.A. Janne, Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment. Semin Respir Crit Care Med, (3): p Noguchi, M., et al., Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer, (12): p Sakao, Y., et al., Prognostic significance of a histologic subtype in small adenocarcinoma of the lung: the impact of nonbronchioloalveolar carcinoma components. Ann Thorac Surg, (1): p
11 17. Lynch, T.J., et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, (21): p Testa, J.R. and J.M. Siegfried, Chromosome abnormalities in human non-small cell lung cancer. Cancer Res, (9 Suppl): p. 2702s-2706s. 19. Paez, J.G., et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, (5676): p Tsao, M.S., et al., Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med, (2): p Sharma, S.V., et al., Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, (3): p Sholl, L.M., et al., Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res, (21): p Yu, J., et al., Mutation-specific antibodies for the detection of EGFR mutations in nonsmall-cell lung cancer. Clin Cancer Res, (9): p Sholl, L.M., et al., Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Mod Pathol, (10): p Shepherd, F.A. and R. Rosell, Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. J Thorac Oncol, Suppl 2: p. S Sasaki, H., et al., EGFR and erbb2 mutation status in Japanese lung cancer patients. Int J Cancer, (1): p Hirsch, F.R., et al., Molecular predictors of outcome with gefitinib in a phase III placebocontrolled study in advanced non-small-cell lung cancer. J Clin Oncol, (31): p West, H.L., et al., Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol, (12): p Miller, V.A., et al., Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol, (9): p Marchetti, A., et al., EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol, (4): p Shigematsu, H., et al., Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, (5): p Lamant, L., et al., High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood, (1): p Morris, S.W., et al., Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-hodgkin's lymphoma. Science, (5151): p
12 34. Swerdlow, S.H., International Agency for Research on Cancer., and World Health Organization., WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. 2008, Lyon, France: International Agency for Research on Cancer. 439 p. 35. Soda, M., et al., Identification of the transforming EML4-ALK fusion gene in non-smallcell lung cancer. Nature, (7153): p Rikova, K., et al., Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell, (6): p Soda, M., et al., A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A, (50): p Koivunen, J.P., et al., EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res, (13): p Rodig, S.J., et al., Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res, (16): p Mino-Kenudson, M., et al., A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry. Clin Cancer Res. 16(5): p Shigematsu, H., et al., Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res, (5): p Stephens, P., et al., Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature, (7008): p Giaccone, G., Clinical impact of novel treatment strategies. Oncogene, (45): p Azzoli, C.G., et al., Trastuzumab in the treatment of non-small cell lung cancer. Semin Oncol, (1 Suppl 4): p
An ongoing research and multiple clinical
TARGETED THERAPIES IN LUNG CANCER Lucian R. Chirieac, MD a, *, Sanja Dacic, MD, PhD b KEYWORDS Lung cancer Adenocarcinoma Squamous Tyrosine kinase inhibitors Molecular pathogenesis ABSTRACT An ongoing
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationOsamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
More informationALK Fusion Oncogenes in Lung Adenocarcinoma
ALK Fusion Oncogenes in Lung Adenocarcinoma Vincent A Miller, MD Associate Attending Physician, Thoracic Oncology Service Memorial Sloan-Kettering Cancer Center New York, New York The identification of
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationEGFR, Lung Cancer and Cytology. Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan.
EGFR, Lung Cancer and Cytology Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan. It is histopathologically divided into two major sub-groups: Small
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationLung cancer is the most common cause of cancer death in
ORIGINAL ARTICLE Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and Mutations in Patients with Adenocarcinoma of the Lung with Bronchioloalveolar Features? Catherine
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationLung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers
Lung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers The Harvard community has made this article openly available. Please share how this access
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationSUBJECT: GENOTYPING - EPIDERMAL GROWTH
MEDICAL POLICY SUBJECT: GENOTYPING - EPIDERMAL GROWTH Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature
More informationFrequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung
HeSMO 6(2) 2015 19 23 DOI: 10.1515/fco-2015-0009 Forum of Clinical Oncology Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung Hanan Ezzat Shafik 1 *,
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationTHE IASLC/ERS/ATS ADENOCARCINOMA CLASSIFICATION RATIONALE AND STRENGTHS
THE IASLC/ERS/ATS ADENOCARCINOMA CLASSIFICATION RATIONALE AND STRENGTHS PULMONARY PATHOLOGY SOCIETY USCAP, BALTIMORE, March 2, 2013 William D. Travis, M.D. Dept of Pathology, Memorial Sloan-Kettering Cancer
More informationHOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY 7 TH Annual New York Lung Cancer Symposium Saturday, November 10, 2012 William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationNon-Small Cell Lung Carcinoma - Myers
Role of Routine Histology and Special Testing in Managing Patients with Non- Small Cell Lung Carcinoma Jeffrey L. Myers, M.D. A. James French Professor Director, Anatomic Pathology & MLabs University of
More informationTest Category: Prognostic and Predictive. Clinical Scenario
Use of Epidermal Growth Factor Receptor (EGFR) Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) to Determine Erlotinib Use as First-line Therapy Test Category: Prognostic
More informationDetection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell lung Cancer (NSCLC) By CISH Technique
Cancer and Clinical Oncology; Vol. 7, No. 1; 2018 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Detection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell
More informationMolecular Diagnostics in Lung Cancer
Molecular Diagnostics in Lung Cancer Mutations in lung carcinomas and their impact on diagnosis and treatment With special thanks to: Barbara Chaitin, MD Medical Director, Esoteric Services AmeriPath Orlando,
More informationDM Seminar. ALK gene rearrangements & ALK targeted therapy in NSCLC Dr Sarat
DM Seminar ALK gene rearrangements & ALK targeted therapy in NSCLC Dr Sarat Introduction Discovery of activating mutations in kinase domain of epidermal growth factor receptor (EGFR) opened a new era of
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More information8/22/2016. Major risk factors for the development of lung cancer are: Outline
Carcinomas of the Lung: Changes in Staging, Adenocarcinoma Classification and Genetics Grace Y. Lin, M.D., Ph.D. Outline Background Staging of Lung Cancer: Review of the 2010 7 th Edition of the AJCC Cancer
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More information1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?
Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations
More informationQuality in Control ALK-Lung Analyte Control (EML4-ALK) ALK-Lymphoma Analyte Control (NPM-ALK)
Quality in Control ALK-Lung Analyte Control (EML4-ALK) ALK-Lymphoma Analyte Control (NPM-ALK) 10 Product Codes: HCL007, HCL008 and HCL009 HCL010, HCL011 and HCL012 Page 1 of Contents 1. What is ALK?...
More informationApplying Genomics to Cancer 21 st September The Frequency of EGFR mutations in Lung Adenocarcinoma: The Cardiff Experience
Applying Genomics to Cancer 21 st September 2015 The Frequency of EGFR mutations in Lung Adenocarcinoma: The Cardiff Experience Aled Daniels R Butler, R Attanoos, H Davies University Hospital of Wales
More informationRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis
5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory
More informationDisclosure of Relevant Financial Relationships NON-SMALL CELL LUNG CANCER: 70% PRESENT IN ADVANCED STAGE
MORPHOLOGY AND MOLECULAR TESTING IN NON-SMALL CELL OF LUNG NEW FRONTIEIRS IN CYTOPATHOLOGY PRACTICE American Society for Cytopathology San Antonio, Texas Sunday March 5, 2017 Disclosure of Relevant Financial
More informationLung cancer is the leading cause of cancer-related death
Molecular Diagnostics of Lung Carcinomas Sanja Dacic, MD, PhD N Context. The development of targeted therapies in the treatment of lung carcinoma is a rapidly growing area that requires a precise histologic
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationRole of molecular studies in the diagnosis of lung adenocarcinoma
& 2012 USCAP, Inc. All rights reserved 0893-3952/12 $32.00 S11 Role of molecular studies in the diagnosis of lung adenocarcinoma Samuel A Yousem Department of Pathology, University of Pittsburgh Medical
More informationThe effi cacy of therapy targeted to a specifi c. Personalized targeted therapy in advanced non small cell lung cancer
PATRICK C. MA, MD, MS Director, Aerodigestive Oncology Translational Research, Department of Translational Hematology and Oncology Research and Department of Solid Tumor Oncology, Taussig Cancer Institute,
More informationInterpretation Guide. Product Name: ALK Cell Line Analyte Control Product Codes: ALK2/CS and ALK2/CB. Page 1 of 9
Interpretation Guide Product Name: ALK Cell Line Analyte Control Product Codes: ALK2/CS and ALK2/CB ALK2/CS/CB_IG_V_001 www.histocyte.com Page 1 of 9 Contents 1. What is ALK?... 2 2. Role of ALK in Cancer...
More informationQuality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024
Quality in Control ROS1 Analyte Control Product Codes: HCL022, HCL023 and HCL024 Contents What is ROS1? 2 The Role of ROS1 in Cancer 3 ROS1 Assessment 3 ROS1 Analyte Control Product Details 4 ROS1 Analyte
More informationPage: 1 of 27. Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Last Review Status/Date: December 2014 Page: 1 of 27 Non-Small-Cell Lung Cancer Description Over half of patients with non-small-cell lung cancer (NSCLC) present with advanced and therefore incurable disease,
More informationNon Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק
Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק 26.06.09 Lecture outlines WHO histological classification Macro/Micro assessment Early diagnosis Minimal pathology Main subtypes SCC, AdCa, LCLC
More informationAnalysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)- Positive Pulmonary Adenocarcinoma. Joungho Han 1
Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)- Positive Pulmonary Adenocarcinoma In Ho Choi Dong Won Kim Sang Yoon Ha 1 Yoon-La Choi 1 Hee Jeong Lee 2 Joungho Han 1 Department
More informationIdentifying ALK+ NSCLC patients for targeted treatment
VENTANA (D5F3) CDx Assay Identifying + NSCLC patients for targeted treatment VENTANA (D5F3) CDx Assay Identify + NSCLC patients eligible for treatment with XORI, ZYKADIA or ALECENSA NSCLC tissue samples
More informationPrimary enteric adenocarcinoma with predominantly signet ring features of the lung: A case report with clinicopathological and molecular findings
CASE REPORT Primary enteric adenocarcinoma with predominantly signet ring features of the lung: A case report with clinicopathological and molecular findings Makoto Nagashima 1, Ayako Moriyama 1, Yasuo
More informationPerformance Improvement Strategies in Non-Small Cell Lung Cancer Audioconference - April 22, 2010
Performance Improvement Strategies in Non-Small Cell Lung Cancer Audioconference - April 22, 2010 OLIVIA FRITZ: Welcome to the Non-Small Cell Lung Cancer Community of Practice Audioconference with expert
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationDifficult Diagnoses and Controversial Entities in Neoplastic Lung
Difficult Diagnoses and Controversial Entities in Neoplastic Lung Lynette M. Sholl, M.D. Associate Pathologist, Brigham and Women s Hospital Chief, Pulmonary Pathology Service Associate Professor, Harvard
More informationIdentification of Novel Variant of EML4-ALK Fusion Gene in NSCLC: Potential Benefits of the RT-PCR Method
International journal of Biomedical science ORIGINAL ARTICLE Identification of Novel Variant of EML4-ALK Fusion Gene in NSCLC: Potential Benefits of the RT-PCR Method Martin K. H. Maus 1, 2, Craig Stephens
More informationCytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics. Mercè Jordà, University of Miami
Cytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics Mercè Jordà, University of Miami Mortality Lung cancer is the most frequent cause of cancer incidence and mortality
More informationAdvances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
More informationALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationPersonalized cancer therapy has attracted much attention
ORIGINAL ARTICLE EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR Shang-Gin Wu, MD,* Yao-Wen Kuo, MD,* Yih-Leong Chang, MD, Jin-Yuan Shih, MD, PhD, Ya-Hui
More informationUnique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
Published OnlineFirst August 11, 2009; DOI: 10.1158/1078-0432.CCR-09-0802 Imaging, Diagnosis, Prognosis Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western
More informationand management of lung cancer Maureen F. Zakowski, M.D. Memorial Sloan-Kettering Cancer Center
The new role of cytology in the diagnosis and management of lung cancer Maureen F. Zakowski, M.D. Memorial Sloan-Kettering Cancer Center Outline Role of cytology in the diagnosis of lung cancer Non-small
More informationLung cancer ranks as the leading cause of cancer-related
Review Article Reflex Testing for Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Fluorescence In Situ Hybridization in Non Small Cell Lung Cancer Mari Mino-Kenudson, MD; Eugene
More informationAHFS Final. line. Criteria Used in. combined. cisplatin. Strength. established was. Non-small Cell Lung. Cancer: of carboplatin and
Drug/Drug Combination: Cetuximab Off-label Use: First-line treatment of advanced non-small Use for Review: cell lung cancer Criteria Used in Selection of Off-labell AHFS Final Determination of Medical
More informationVENTANA ALK (D5F3) Rabbit Monoclonal Primary Antibody. ALK IHC Biomarker Testing Aiding in patient diagnosis
VENTANA (D5F3) Rabbit Monoclonal Primary Antibody IHC Biomarker Testing Aiding in patient diagnosis 2 IHC Biomarker Testing Lung cancer is the leading cause of death Lung cancer is the most prevalent form
More informationRearrangement of the anaplastic lymphoma kinase (ALK)
Brief Report Clinical Implications of Variant ALK FISH Rearrangement Patterns Xin Gao, MD,* Lynette M. Sholl, MD,* Mizuki Nishino, MD,* Jennifer C. Heng, BS, Pasi A. Jänne, MD, PhD,* and Geoffrey R. Oxnard,
More informationPTCL: morphology and pathobiology Anaplastic large cell lymphoma
PTCL: morphology and pathobiology Anaplastic large cell lymphoma Stefano A. Pileri Director Haematopathology European Institute of Oncology - Milan Alma Mater Professor of Pathology Bologna University
More informationPersonalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader
Personalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader Agenda PHC Approach Provides Better Patient Outcome FMI offers Comprehensive Genomic Profiling,
More informationREVIEWS. Personalized medicine in lung cancer: what we need to know. Tony S. K. Mok
Personalized medicine in lung cancer: what we need to know Tony S. K. Mok Abstract Lung cancer is a complex and often fatal disease. The recent discovery of activating mutations in EGFR and fusion genes
More informationPRACTICE GUIDELINE SERIES
ELLIS et al. PRACTICE GUIDELINE SERIES The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent nonsmall-cell lung cancer: a Canadian
More informationHER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam
HER2 status assessment in breast cancer Marc van de Vijver Academic Medical Centre (AMC), Amsterdam 13e Bossche Mamma Congres 17 th June 2015 Modern cancer therapies are based on sophisticated molecular
More informationCAP Laboratory Improvement Programs. Worldwide Frequency of Commonly Detected EGFR Mutations
CAP Laboratory Improvement Programs Worldwide Frequency of Commonly Detected EGFR Mutations Rondell P. Graham, MBBS; Amanda L. Treece, MD; Neal I. Lindeman, MD; Patricia Vasalos, BS; Mu Shan, BS; Lawrence
More informationCorporate Medical Policy
Corporate Medical Policy Proteomic Testing for Targeted Therapy in Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomic_testing_for_targeted_therapy_in_non_small_cell_lung_cancer
More informationTargeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations
Review Article Page 1 of 5 Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations Gérard A. Milano Oncopharmacology Unit, EA 3836 UNS, Centre Antoine Lacassagne,
More informationWhen Policy Topic is covered Crizotinib may be considered medically necessary in patients 18 years or older when the following criteria are met:
Xalkori (crizotinib) Policy Number: 5.01.539 Last Review: 6/2018 Origination: 7/2012 Next Review: 6/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for crizotinib
More informationPersonalized Genetics
Personalized Genetics Understanding Your Genetic Test Results Tracey Evans, MD September 29, 2017 Genetics 101 Punnett Square Genetic Pedigree 2 Genetics 101 Punnett Square Genetic Pedigree 3 It s not
More informationMET skipping mutation, EGFR
New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM
More informationMolecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory
2.04.45 Molecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date November 26, 2014 Original Policy Date November
More informationIntroduction: Overview of Current Status of Lung Cancer Predictive Biomarkers
Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers Program 7:15 7:40 Translocations as predictive biomarkers in lung cancer: Overview Mari Mino Kenudson, MD 7:40 8:05 Translocation
More informationPersonalized Medicine in Oncology and the Implication for Clinical Development
THE POWER OFx Experts. Experienc e. Execution. Personalized Medicine in Oncology and the Implication for Clinical Development Jamal Gasmi MD, PhD, Medical Director, Medpace Introduction The notable success
More informationMolecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
SPECIAL Article Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Guideline from the College of American Pathologists, International Association
More informationNon-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
Journal of Pathology and Translational Medicine 2016; 50: 197-203 ORIGINAL ARTICLE Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases Taebum
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationRearrangement of the ALK gene occurs in approximately
Original Article Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas Lynette M. Sholl, MD,* Stanislawa Weremowicz, PhD, * Stacy W. Gray, MD, Kwok-Kin
More informationMolecular genetics and prognosis of lung cancer in young patients: Research highlights SONG Yong, PAN Xian-hui
Med J Chin PLA, Vol. 42, No. 3, March 1, 2017 181 ( ) (CSCO) (IASLC) Translational Lung Cancer Research Journal of Thoracic Disease Military Medical Research 120 SCI81 66 [ ] ( 50 ) (NSCLC) (EGFR) 4- (EML4-ALK)
More informationMolecular Pathobiology of Lung Cancer. William K. Funkhouser, MD PhD Department of Pathology and Lab Medicine University of North Carolina
Molecular Pathobiology of Lung Cancer William K. Funkhouser, MD PhD Department of Pathology and Lab Medicine University of North Carolina Outline Lung Anatomy Lung Carcinoma Classification & Morphology
More informationRob Ross, MD. Infinity Pharmaceuticals March 9 th, 2011
Heat Shock Protein 90 (Hsp90) Inhibition as a Potential Novel Approach to the Treatment of Patients with ALK Mutated Non-small Cell Lung Cancer (NSCLC) Rob Ross, MD Infinity Pharmaceuticals March 9 th,
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationEGFR MUTATIONS IN NON SMALL CELL LUNG CANCER PATIENTS IN SOUTH AFRICA
EGFR MUTATIONS IN NON SMALL CELL LUNG CANCER PATIENTS IN SOUTH AFRICA Sze Wai Chan A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, in partial
More informationOriginal Articles. Implications for Optimal Clinical Testing
Original Articles Comparison of Reverse Transcription-Polymerase Chain Reaction, Immunohistochemistry, and Fluorescence In Situ Hybridization Methodologies for Detection of Echinoderm Microtubule-Associated
More informationIn the era of personalized cancer therapy, targeted therapy
Original Article Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations Yen-Fu Chen, MD,* Min-Shu
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationGENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)
CANCER (NSCLC) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are
More informationLung Cancer in Women: A Different Disease? James J. Stark, MD, FACP
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine Eastern Virginia Medical
More informationClinicopathologic Characteristics of EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC) in Central New York
North American Journal of Medicine and Science Jan 2018 Vol 11 No.1 1 Original Research Clinicopathologic Characteristics of EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC) in Central New York Daniel
More informationImmunohistochemical screening for ALK fusion gene in signet-ring cell gastric carcinoma.
Biomedical Research 217; Special Issue: S423-S428 ISSN 97-938X www.biomedres.info Immunohistochemical screening for ALK fusion gene in signet-ring cell gastric carcinoma. Liang Chang, Bingjie Huo, Yalei
More informationBiomedical Research 2017; 28 (14): ISSN X
Biomedical Research 2017; 28 (14): ISSN 0970-938X www.biomedres.info Study of the relationship between EGFR mutation status and bone metastasis in advanced lung adenocarcinoma. Xiaoye Ai, Adalati Yasheng,
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationPredictive Assays in Radiation Therapy
Outline Predictive Assays in Radiation Therapy Radiation Biology Introduction Early predictive assays Recent trends in predictive assays Examples for specific tumors Summary Lecture 4-23-2014 Introduction
More informationThe Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer
The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer Nathan A. Pennell, M.D., Ph.D. Assistant Professor Solid Tumor Oncology Cleveland Clinic Taussig Cancer Institute www.cancergrace.org
More informationAdvanced, Non-Small Cell Lung Cancer with Anaplastic Lymphoma Kinase Rearrangement: Case Report And Literature Review
www.journalofcancerology.com PERMANYER J Cancerol. 2015;2:34-8 JOURNAL OF CANCEROLOGY CLINICAL CASE Advanced, Non-Small Cell Lung Cancer with Anaplastic Lymphoma Kinase Rearrangement: Case Report And Literature
More informationA nonresponding small cell lung cancer combined with adenocarcinoma
Case Report A nonresponding small cell lung cancer combined with adenocarcinoma Hongyang Lu 1,2, Shifeng Yang 3 1 Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (Lung
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More informationA Correlation between EGFR Gene Mutation Status and Bronchioloalveolar Carcinoma Features in Japanese Patients with Adenocarcinoma
Jpn J Clin Oncol 26;36(2)69 75 doi:.93/jjco/hyi228 Original Articles A Correlation between EGFR Gene Mutation Status and Bronchioloalveolar Carcinoma Features in Japanese Patients with Adenocarcinoma Hiroshi
More informationThe epidermal growth factor receptor (EGFR) is a promising
ORIGINAL ARTICLE Clinical Significance of Epidermal Growth Factor Receptor Gene Mutations on Treatment Outcome after First-line Cytotoxic Chemotherapy in Japanese Patients with Non-small Cell Lung Cancer
More information